These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10155313)

  • 61. Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study.
    Fagnani D; Isa L; Verga MF; Nova P; Casartelli C; Filipazzi V; Danova M; Farina G; Pugliese P; Fava S; Bertolini A; Cimminiello C; Boracchi P; Marano G; Panzarino C;
    Tumori; 2014; 100(5):491-8. PubMed ID: 25343541
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data.
    Gunzer K; Clarisse B; Lheureux S; Delcambre C; Joly F
    Expert Opin Biol Ther; 2010 Apr; 10(4):615-30. PubMed ID: 20218922
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The use of lenograstim (Granocyte) in chemotherapy for ovarian cancer.
    Roongpisuthipong A; Suphanit I; Luamprapat A; Senapad S
    Asian Pac J Allergy Immunol; 1998 Mar; 16(1):43-7. PubMed ID: 9681128
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Use of recombinant human granulocyte colony-stimulating factor prior to autologous bone marrow transplantation in dogs with lymphoma.
    Lane AE; Chan MJ; Wyatt KM
    Am J Vet Res; 2012 Jun; 73(6):894-9. PubMed ID: 22620705
    [TBL] [Abstract][Full Text] [Related]  

  • 65. G-CSF after PBSC transplantation.
    Ojeda E; Garcia-Bustos J; Aguado MJ; Luaces MR; Arrieta R; Hernandez-Navarro F
    Br J Haematol; 1998 Jun; 101(3):594-6. PubMed ID: 9633910
    [No Abstract]   [Full Text] [Related]  

  • 66. Delayed administration of granulocyte colony-stimulating factor after autologous bone marrow transplantation: effect on granulocyte recovery.
    Vey N; Molnar S; Faucher C; Le Corroller AG; Stoppa AM; Viens P; Bouabdallah R; Camerlo J; Novakovitch G; Mannoni P
    Bone Marrow Transplant; 1994 Nov; 14(5):779-82. PubMed ID: 7534161
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacokinetics of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) in healthy male volunteers.
    Houston AC; Stevens LA; Cour V
    Br J Clin Pharmacol; 1999 Mar; 47(3):279-84. PubMed ID: 10215752
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancy.
    Nemunaitis J; Singer JW; Buckner CD; Mori T; Laponi J; Hill R; Storb R; Sullivan KM; Hansen JA; Appelbaum FR
    Bone Marrow Transplant; 1991 Jan; 7(1):49-52. PubMed ID: 2043878
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
    Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
    J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The optimal dose of glycosylated recombinant human granulocyte colony stimulating factor for use in clinical practice: a review.
    Marty M
    Eur J Cancer; 1994; 30A Suppl 3():S20-5. PubMed ID: 7535068
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combined use of growth factors to stimulate the proliferation of hematopoietic progenitor cells after autologous bone marrow transplantation for lymphoma patients.
    Lemoli RM; Fortuna A; Fogli M; Rosti G; Gherlinzoni F; Visani G; Catani L; Gozzetti A; Tura S
    Acta Haematol; 1996; 95(3-4):164-70. PubMed ID: 8677737
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
    Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
    J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost considerations in therapy with myeloid growth factors.
    Glaspy JA; Jakway J
    Am J Hosp Pharm; 1993 Jul; 50(7 Suppl 3):S19-26. PubMed ID: 7689789
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Clinical evaluation of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in autologous bone marrow transplantation].
    Takahashi S; Asano S; Masaoka T; Takaku F; Niitsu Y; Shibuya A; Saito H; Sekine I; Sanpi K; Hanada R
    Rinsho Ketsueki; 1991 Mar; 32(3):221-6. PubMed ID: 1710295
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High pregnancy rates with administration of granulocyte colony-stimulating factor in ART-patients with repetitive implantation failure and lacking killer-cell immunglobulin-like receptors.
    Würfel W; Santjohanser C; Hirv K; Bühl M; Meri O; Laubert I; von Hertwig I; Fiedler K; Krüsmann J; Krüsmann G
    Hum Reprod; 2010 Aug; 25(8):2151-2; author reply 2152. PubMed ID: 20522442
    [No Abstract]   [Full Text] [Related]  

  • 77. Teicoplanin-induced leucopenia with immediate resolution after administration of G-CSF.
    Patel P; Sandoe J; Baig W
    BMJ Case Rep; 2012 Aug; 2012():. PubMed ID: 22891005
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Recombinant granulocyte colony-stimulating factor in acute myelogenous leukemia.
    Munck JN; Deacaudin D; Koscielny S
    N Engl J Med; 1995 Oct; 333(17):1155-6. PubMed ID: 7565966
    [No Abstract]   [Full Text] [Related]  

  • 79. Haemopoietic cells mobilised into the circulation by lenograstim as alternative to bone marrow for allogeneic transplants.
    Baumann I; Testa NG; Lange C; de Wynter E; Luft T; Dexter TM; van Hoef ME; Howell A
    Lancet; 1993 Feb; 341(8841):369. PubMed ID: 7679177
    [No Abstract]   [Full Text] [Related]  

  • 80. [Prescription of a hematopoietic growth factor, lenograstim, in current practice. Results and commentaries of a national survey from April 1995 to March 1996].
    Maurice-Tison S; Schuller MP; Salamon R
    Presse Med; 1998 Jul 4-11; 27(24):1203-7, 211. PubMed ID: 9767771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.